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Since 1999, when the Food and Drug Administration gave 
its approval for use in mechanically ventilated patients 
in intensive care unit (ICU), dexmedetomidine has 
gained a growing interest among intensivists worldwide. 
Over the last years, a series of studies on the use of 
dexmedetomidine in different settings showed that it may 
provide significant advantages also in the perioperative 
period and for procedures requiring sedation outside the 
operating room (1). Nevertheless, sedation of critically ill 
patients remains the cornerstone use of dexmedetomidine. 
In fact, in 2011 the European Medicines Agency approved 
the use of dexmedetomidine only for light sedation in ICU 
patients (Richmond Agitation-Sedation Scale (RASS) score 
of between 0 and −3). To this goal, the administration of 
dexmedetomidine seems to provide significant advantages 
in comparison with traditional sedatives by reducing the 
duration of mechanical ventilation, the ICU stay (2) and the 
occurrence of delirium (3). Although the literature data are 
still inconclusive, dexmedetomidine has been also proposed 
for the management of adult ICU patients with delirium 
unrelated to alcohol or benzodiazepine withdrawal (3). A 
clinical experience published early this year showed that 
dexmedetomidine may be useful as a rescue drug for treating 
agitation due to delirium refractory to haloperidol in 132 ICU 
non-intubated patients (4). To evaluate the potential benefits 
provided by the use of dexmedetomidine for treating agitated 
delirium, Reade and coworkers conducted a multinational, 
randomized, double-blind study including 71 mechanically 
ventilated patients in whom extubation was considered 
inappropriate because of the severity of agitation and 
delirium (DahLIA trial) (5). The authors demonstrated 
that dexmedetomidine compared to placebo group provide 
a significant decrease of mechanical ventilation time by 
about 17 hours (at 7 days) and an accelerate resolution of 
delirium. These results were associated to a shortening of 
ICU and hospital length of stay in the dexmedetomidine 
group. As expected, patients treated with dexmedetomidine 
received less propofol, antipsychotics and opioids, but 
a higher percentage of these patients were treated with 
antipsychotics 24 hours prior to randomization. The 
authors concluded that in mechanically ventilated patients 
with agitated delirium the addition of dexmedetomidine to 
standard therapies may be beneficial. 
This pragmatic trial provides important information for 
the daily management of patients intubated with agitated 
delirium, particularly because the protocol was based almost 
entirely on an easy to apply nursing protocol. The trial also 
confirmed the safety of the drug by reporting a very low 
incidence (only 5.3%) of bradycardia in the dexmedetomidine 
group, which is considerably lower than incidence reported 
in previous trials: MENDS (6) (17%), SEDCOM (7) (42.2%) 
and MIDEX/PRODEX (8) (14.2–13%).
Although the study resulted positive, there are some 
points that need to discussed to get more insight the 
true meaning of DahLIA trial. First of all, it should 
be remembered that the study was early stopped. The 
original statistical plan considered that 96 patients had 
to be enrolled in order to demonstrate a decrease of 
20 hours of ventilation between the two groups but only 
74 patients were randomized and of these only 71 patients 
were subjected to analysis. Although the authors provided a 
post-hoc simulation that indicated only a 7% probability 
of null effect if the trial would have included the planned 
96 patients, the early trial stop associated to the low number 
of patients studied may hamper the strength of the results 
observed. In addition, it is noteworthy that for enrolling 
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74 more than 20,000 patients have been screened (<0.5%). 
The characteristics of the investigated population are very 
uncommon and, thus, the true impact of the study results in 
clinical practice may result marginal. 
A further point to be discussed concerns the enrolled 
patients who received tracheostomy. In fact, a much 
greater proportion of patients in the dexmedetomidine 
group (17.9%) were tracheostomized compared to the 
placebo group (6.9%). Although the role of tracheostomy 
in critically ill patients is still debated, it has been 
demonstrated that tracheostomy may have an indirect 
effect on mechanical ventilation time by the reduction 
of ventilator-associated pneumonia and sepsis risk (9). 
To evaluate the possible bias related to the difference in 
tracheostomy proportions between the two groups, the 
investigators performed a sensitivity analysis by excluding 
patients with tracheostomy and concluded that there 
were no significant differences compared to the overall 
results of the primary endpoint. However, it is important 
to point out that 13% of the enrolled patients underwent 
tracheostomy during the study period which appears to be a 
large percentage considering study admission criterion was 
represented by a need of mechanical ventilation attributable 
only to a high degree of agitation. 
Recently, Turunen et al. (10) have highlighted a median 
sparing ICU total cost of 2,656 euros per patient in the 
MIDEX/PRODEX trials receiving dexmedetomidine. 
Carrasco et al. (4) demonstrated a favorable cost-effectiveness 
profile of dexmedetomidine compared to haloperidol in the 
management of refractory delirium with a direct benefit 
due to the decrease of ICU stay and also an intangible 
or difficult-to-quantify benefit resulting by the potential 
decrease of orotracheal intubation risk. Consequently, the 
direct cost of dexmedetomidine, that is 17 times higher 
than haloperidol, was fully covered by direct and indirect 
benefits. In DahLIA study, 77% of the patients in the 
dexmedetomidine group were extubated within 48 hours 
after randomization (20.5% within 24 hours) against 59.4% 
in the placebo group. In addition, despite no significant, the 
dexmedetomidine group showed a shorter ICU (1.5 days) 
and hospital length of stay. By applying the same approach 
proposed by Carrasco et al. (4), also the DahLIA study 
confirms the financial cost-benefit provided by the use of 
dexmedetomidine in ICU patients with refractory agitated 
delirium. 
Intensivists and nurses face daily difficulties related 
to delirium in intubated patients and, unfortunately, the 
available tools are limited. In this context, dexmedetomidine 
may represent a valuable option but to our knowledge 
only few studies have shown its superiority compared to 
other strategies (4,5,11). Therefore, further appropriate 
studies and clinical experiences are needed to support the 
widespread use of dexmedetomidine in delirious patients. 
Indeed, at least 29 trials dealing with this issue are underway 
(www.clinicaltrial.gov) and, thus, in the coming years 
we could find out whether the positive results observed 
in the DahLIA trial represent only the first chapter of 
the successfully use of dexmedetomidine to lessen ICU 
agitated-delirium.
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